Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Chennai, Dec. 13 -- Highlights: ...

The health sector witnesses significant developments with Eli Lilly's promising weight-loss drug trials and a $40 million ...

Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks ...

The FDA has recalled thousands of Ziac blood pressure tablets after traces of a cholesterol drug were found during testing, ...

These players are well-positioned to potentially gain next year -- and over time.

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

The company ended the third quarter of 2025 with $715 million in cash, a war chest deemed sufficient to fund both ongoing VANQUISH trials to completion. Research and development expenses jumped to $90 ...